Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias

Publisher Website
Google Scholar
Abstract
Atrial arrhythmias are a common problem in cardiological practice. Despite the availability of several antiarrhythmic drugs there is a medical need for safer and more efficient treatments. The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. This review summarises patents claiming such compounds. The chemistry and biological data disclosed in these patents are discussed in light of recent work demonstrating the antiarrhythmic effects of Kv1.5 blockers in vivo.